Casin

2 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Funder: Deutsche Forschungsgemeinschaft

Animals1
Cells1

Outcomes

Motor function

upin mice1

1 study

Casin improves motor function in mice (fully restored).
“inhibition of the age hyperactivated Rho GTPase CDC42 with CASIN fully restored motor function”
Reviewin alpha-synuclein oligomer model
Targeting CDC42 with CASIN Reprograms Cell-Type-Specific Transcriptomes and MAPK-Driven Transcription Factor Networks in the Aging Brain
bioRxiv14 Aug 2026Preprint

Transcriptional alterations

downin mice1

1 study

Casin decreases transcriptional alterations in mice.
“CASIN robustly reverted PD-related transcriptional alterations at 24 months”
Animalsin alpha-synuclein-induced mouse model of Parkinson's diseasebrain
Targeting CDC42 with CASIN Reprograms Cell-Type-Specific Transcriptomes and MAPK-Driven Transcription Factor Networks in the Aging Brain
bioRxiv14 Aug 2026Preprint